| abstract |
The present invention provides methods for the assessment of risk of developing acute coronary syndrome (ACS), arterial inflammation, or ACS-associated impaired vascular function, in smokers and non-smokers using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's risk of developing ACS, arterial inflammation, or ACS-associated impaired vascular function. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided. |